AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25357174
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment of cryogen cooling only
Trial: 18411009
Drug: Daily Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Sleep Interference Scale (DSIS)
Trial: 12969711
Drug: N,O-carboxymethylchitosan (NOCC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N,O-carboxymethylchitosan (NOCC) - 200 mL of 1% NOCC gel followed by 100 mL of 2% NOCC solution
Trial: 22513879
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injections
Trial: 1378783
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release gallopamil 100mg twice daily
Trial: 3514487
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg chlorthalidone
Trial: 3514487
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 50 mg atenolol and 12.5 mg chlorthalidone
Trial: 3514487
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atenolol-chlorthalidone
Trial: 9863872
Drug: Dideoxynucleoside monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideoxynucleoside monotherapy (zidovudine)
Trial: 9863872
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (zidovudine, zalcitabine, didanosine)
Trial: 7897523
Drug: 8 drugs
RxNorm normalized name: goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 drugs in 1 day regimen followed by high-dose methotrexate (12 g/m2)
Trial: 7897523
Drug: Postirradiation chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postirradiation chemotherapy with four 8/1 courses monthly
Trial: 7897523
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of radiation doses in Group B
Trial: 7897523
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment including sandwich chemotherapy
Trial: 2495900
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg sodium cromoglycate metered dose inhaler
Trial: 2495900
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sodium cromoglycate metered dose inhaler
Trial: 799981
Drug: New analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New analgesic compound (propoxyphene, acetaminophen, caffeine, hydroxyzine)
Trial: 799981
Drug: Plain acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain acetaminophen
Trial: 16511927
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment approach (control group)
Trial: 27635609
Drug: Cytoflavin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (20 ml per 400 ml of 5% glucose solution, intravenously, 1 time a day for 10 days, then 2 tablets 2 times a day for a month)
Trial: 16188154
Drug: Concurrent radio-chemotherapy
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent radio-chemotherapy (NVB + DDP plus radiotherapy)
Trial: 16188154
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (NVB + DDP)
Trial: 12358338
Drug: Nedocromil (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil (two puffs of 2 mg)
Trial: 12358338
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nedocromil and salbutamol
Trial: 2176235
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg twice (group A)
Trial: 2176235
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once (group B)
Trial: 7000106
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LAS) 12.5 mg kg‐1
Trial: 7000106
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (LAS) 25 mg kg‐1
Trial: 7000106
Drug: Oxycodone 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.15 mg kg‐1
Trial: 30370450
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 IU) after memory retrieval
Trial: 30370450
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 IU) without retrieval
Trial: 28024952
Drug: Prime-boost EVD
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prime-boost EVD vaccine
Trial: 21950726
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg/d
Trial: 17694386
Drug: Daily low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low dose plasma exchange
Trial: 15780697
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment (not specified dosage or duration)
Trial: 7942937
Drug: Intermittent very-low-calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent very-low-calorie diet (VLCD) of 400 to 500 kcal per day for 12 weeks, alternating with a balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Trial: 7942937
Drug: Balanced low-calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Trial: 2897388
Drug: loratadine, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loratadine, 40 mg once daily
Trial: 2897388
Drug: terfenadine, 60
RxNorm normalized name: Terfenadine, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine, 60 mg twice daily
Trial: 30100375
Drug: Mogamulizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (1.0 mg/kg intravenously weekly for the first 28-day cycle, then on days 1 and 15 of subsequent cycles)
Trial: 30100375
Drug: Vorinostat (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (400 mg daily)
Trial: 24815533
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg QD
Trial: 24815533
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg QD
Trial: 22205424
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy for flight phobia (specific dosage and duration not mentioned)
Trial: 22205424
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy for flight phobia
Trial: 18541590
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation, mean daily dose of 86 microg (3440 IU) adjusted every 2 months based on serum 25(OH)D concentration.
Trial: 18541590
Drug: Computer simulations
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer simulations for optimal daily dose of vitamin D(3).
Trial: 18541590
Drug: Projected dose-response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Projected dose-response curves for different baseline 25(OH)D concentrations.
Trial: 11054193
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled flunisolide 2 mg/d
Trial: 9089000
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (tablet Krewel)
Trial: 9089000
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation 1 (suspension Krewel)
Trial: 9089000
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation 2 (tablet Muskel Trancopal)
Trial: 8447567
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium 50 mg on the evening before operation and 25 mg on the morning of the operation
Trial: 8447567
Drug: Flunitrazepam 1
RxNorm normalized name: flunitrazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1 mg p.o. on the evening before the operation
Trial: 3082613
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone treatment (100 micrograms thyroxin)
Trial: 29669934
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH)
Trial: 8299238
Drug: Soy diet
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy diet plus 5 g/day of fish oil (SD + FO)
Trial: 2834502
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Kabi 2165)
Trial: 2834502
Drug: Non-fractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fractionated heparin
Trial: 19096768
Drug: Letrozole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (5 years' monotherapy)
Trial: 19096768
Drug: Tamoxifen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (5 years' monotherapy)
Trial: 19096768
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (2 years tamoxifen followed by 3 years letrozole)
Trial: 19096768
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (2 years letrozole followed by 3 years tamoxifen)
Trial: 16870078
Drug: Sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 100 mg tablets
Trial: 10229430
Drug: Active nonsteroidal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nonsteroidal antiinflammatory drug (NSAID)
Trial: 2010061
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (500 mg/day)
Trial: 7099731
Drug: Methylphenidate (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (dosage adjusted based on nervous system classification)
Trial: 31936720
Drug: Walnut consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut consumption (Juglans regia L.) for 4 weeks
Trial: 22183214
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg synthetic conjugated estrogens-B
Trial: 22183214
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg synthetic conjugated estrogens-B
Trial: 20815158
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (Propranolol, Atenolol, Pindolol)
Trial: 9453014
Drug: Beta-blocker (BBL)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (BBL)
Trial: 9453014
Drug: Converting enzyme
RxNorm normalized name: Prohormone converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting enzyme inhibitor (CEI)
Trial: 9453014
Drug: Alpha-blocker (ABL)
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker (ABL)
Trial: 31619335
Drug: Medetomidine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medetomidine (bolus dose, 5 μg kg‐1; CRI, 3.5 μg kg‐1 hour‐1)
Trial: 31619335
Drug: Detomidine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (bolus dose, 10 μg kg‐1; CRI, 6 μg kg‐1 hour‐1)
Trial: 31554370
Drug: Piperacillin/Tazobactam (PIP/TZO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/Tazobactam (PIP/TZO) 320 mg/kg/day divided every 8 hours
Trial: 31554370
Drug: Ceftazidime 100
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 100 mg/kg/day divided every 8 hours plus Amikacin 15 mg/kg/day once daily
Trial: 27522630
Drug: CA125-guided therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CA125-guided therapy (CA125 strategy)
Trial: 20861586
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg NWP06 (extended-release methylphenidate)
Trial: 20861586
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg immediate-release methylphenidate (IR MPH)
Trial: 20861586
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg NWP06
Trial: 16422874
Drug: On-demand tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-demand tadalafil (20 mg)
Trial: 16422874
Drug: Daily tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tadalafil (10 mg)
Trial: 12660257
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (two different regimens)
Trial: 10618463
Drug: Chronic imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic imipramine treatment
Trial: 1862965
Drug: Multicomponent endotracheal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent endotracheal anesthesia with controlled lung ventilation and postoperative intramuscular analgesia with non-narcotic and narcotic analgesics (Group I)
Trial: 1862965
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 2.5% trimecaine solution combined with adrenaline and small morphine doses at the upper thoracic segment level, with postoperative analgesia for 18 hours (Group II)
Trial: 6412263
Drug: Bupropion (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (100, 200, 400 mg)
Trial: 6412263
Drug: Dextroamphetamine (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (15, 30 mg)
Trial: 30720444
Drug: 0.9% cadexomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% cadexomer iodine ointment plus standard care
Trial: 18163919
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (LDD) 20 mg twice a day for 10 weeks
Trial: 9649964
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (10, 30, 56, and 100 mg)
Trial: 9649964
Drug: LY297802 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY297802 (0.1, 0.3, 0.56, and 1 mg)
Trial: 7675376
Drug: Intracervical PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical PGE2 gel 0.5 mg administered at 6-hour intervals
Trial: 2044014
Drug: Isosorbide-5-mononitrate 60
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate 60 mg once daily
Trial: 2044014
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 30 mg qid
Trial: 28474780
Drug: Abaloparatide-SC (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide-SC (80 mcg daily subcutaneous injections for 18 months)
Trial: 24576893
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 50% glucose only
Trial: 24576893
Drug: 10 units
RxNorm normalized name: Omnipod GO 10 Units/Day Pods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 units of insulin with 100 ml of 50% glucose (50 g)
Trial: 17523386
Drug: Allergovit 6-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergovit 6-grass pollen preparation
Trial: 9849475
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CP) every 28 days for six courses
Trial: 9849475
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 every 28 days for six courses
Trial: 9849475
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CP)
Trial: 12860938
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2
Trial: 9849475
Drug: Platinum second-line
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum second-line therapy
Trial: 8300993
Drug: Training with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training with a combination of food models and life-sized food photographs (experimental group, n = 18)
Trial: 2230213
Drug: Topical all‐trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical all‐trans retinoic acid (0.05%) applied to the forearms for 6 months
Trial: 2230213
Drug: Topical all‐trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical all‐trans retinoic acid (0.05%)
Trial: 24001533
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab
Trial: 21896561
Drug: Moxifloxacin iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin iv 400 mg once daily followed by oral 400 mg once daily
Trial: 21896561
Drug: Piperacillin/tazobactam (TZP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (TZP) iv 4.0/0.5 g thrice daily followed by oral amoxicillin/clavulanate (AMC) 875/125 mg twice daily
Trial: 21896561
Drug: Moxifloxacin iv/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin iv/oral
Trial: 21896561
Drug: Piperacillin/tazobactam (TZP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC)
Trial: 15590951
Drug: Secondary surgical
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary surgical cytoreduction plus chemotherapy
Trial: 9587124
Drug: Early adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early adjuvant radiation therapy (RT)
Trial: 9587124
Drug: Salvage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage radiation therapy (RT)
Trial: 806293
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs combined (disodium cromoglycate and betamethasone 17 valerate)
Trial: 31268555
Drug: Staccato alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staccato alprazolam 0.5 mg
Trial: 24079396
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) treatment
Trial: 16160572
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) gel applied
Trial: 12834649
Drug: Cognitive-behavioral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatments (CBT)
Trial: 10825372
Drug: Mifepristone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone administration
Trial: 1996621
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion (10 mg/h) after pretreatment with dexamethasone (4 mg/day) for 4 or 6 days